Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Brivanib · 1 trial · 1 indication
Defined as the percentage of patients with complete response, partial response, or stable disease at 12 weeks from randomization by RECIST v1.1.
Defined as the time from random assignment to radiologic disease progression.
| Arm | Type | Description |
|---|---|---|
| Brivanib 800 mg, QD + BSC | EXPERIMENTAL | - |
| Brivanib 400 mg, BID + BSC | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Brivanib 800 mg, QD | DRUG | Brivanib Alaninate 800 mg QD, PO |
| Brivanib 400 mg, BID | DRUG | Brivanib Alaninate 400 mg BID, PO |
Inclusion Criteria: * 18-75 years, male or female * Histologically or cytologically confirmed or the clinical diagnosis standard confirmed hepatocellular carcinoma (HCC) patients * Failure or intolerance to prior treatment with chemotherapy and/or targeted therapy * Liver function status Child-Pugh...
Brivanib is an investigational small molecule being studied for the treatment of Hepatocellular Carcinoma (HCC), a type of liver cancer. It is being developed for patients with previously treated advanced HCC, specifically in a Chinese patient population. The drug is currently in Phase 2 clinical development and is not yet approved.
Brivanib is being developed by Zai Lab Limited, a biopharmaceutical company traded on the stock exchange under the ticker symbol ZLAB. The company is conducting clinical trials for Brivanib in the oncology therapeutic area, focusing on Hepatocellular Carcinoma (HCC).
Brivanib is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. A Phase 2 study of Brivanib in Chinese patients with previously treated advanced HCC has been completed, but the drug remains in clinical development.
Brivanib has one completed clinical trial, identified by the National Clinical Trial number NCT03516071. This was a Phase 2 study in Chinese patients with previously treated advanced Hepatocellular Carcinoma (HCC). The trial enrolled 90 participants and was a controlled, randomized study, though it was not double-blind.
Brivanib is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for Hepatocellular Carcinoma (HCC). The completed Phase 2 trial, NCT03516071, was conducted in China, but no approval status has been established for Brivanib in any market.
Brivanib is a small molecule, but its specific molecular target has not been disclosed in the available information. As an investigational oncology drug, it is being studied for its potential effect in treating advanced Hepatocellular Carcinoma (HCC), though its exact mechanism of action is not detailed here.